دورية أكاديمية
أعرض في EDS

Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level.

التفاصيل البيبلوغرافية
العنوان: Skeletal muscle adaptations in patients with lung cancer: Longitudinal observations from the whole body to cellular level.
المؤلفون: Snoke DB; Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA., Bellefleur E; Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA., Rehman HT; Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.; University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, Vermont, USA., Carson JA; Department of Physical Therapy, The University of Tennessee Health Science Center, Memphis, Tennessee, USA., Poynter ME; Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA., Dittus KL; Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.; University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, Vermont, USA., Toth MJ; Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.; University of Vermont Cancer Center, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
المصدر: Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2023 Dec; Vol. 14 (6), pp. 2579-2590. Date of Electronic Publication: 2023 Sep 19.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-6009 (Electronic) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Berlin : John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders
Original Publication: Heidelburg : Springer-Verlag
مواضيع طبية MeSH: Lung Neoplasms*/pathology , Carcinoma, Non-Small-Cell Lung*/pathology, Humans ; Male ; Female ; Middle Aged ; Muscle, Skeletal/pathology ; Muscle Fibers, Skeletal/pathology ; Muscle Strength
مستخلص: Background: Cancer and its treatment can adversely affect skeletal muscle, impacting physical function, treatment response and survival. No studies, however, have comprehensively characterized these muscle adaptations longitudinally in human patients at the cellular level.
Methods: We examined skeletal muscle size and function from the whole body to the sub-cellular level in 11 patients with non-small cell lung cancer (NSCLC; 6 male/5 female, mean age 58 ± 3 years) studied over a 2-month observation period starting during their first cycle of standard of care cancer treatment and in 11 age- and sex-matched healthy controls (HC) without a current or past history of cancer. Biopsies of the vastus lateralis were performed to assess muscle fibre size, contractility and mitochondrial content, along with assessments of physical function, whole muscle size and function, and circulating cytokines.
Results: Body weight, composition and thigh muscle area and density were unaltered over time in patients with NSCLC, while muscle density was lower in patients with NSCLC versus HC (P = 0.03). Skeletal muscle fibre size decreased by 18% over time in patients (all P = 0.02) and was lower than HC (P = 0.02). Mitochondrial fractional area and density did not change over time in patients, but fractional area was lower in patients with NSCLC compared with HC (subsarcolemmal, P = 0.04; intermyofibrillar, P = 0.03). Patients with NSCLC had higher plasma concentrations of IL-6 (HC 1.40 ± 0.50; NSCLC 4.71 ± 4.22; P < 0.01), GDF-15 (HC 569 ± 166; NSCLC 2071 ± 1168; P < 0.01) and IL-8/CXCL8 (HC 4.9 ± 1.8; NSCLC 10.1 ± 6.0; P = 0.02) compared with HC, but there were no changes in inflammatory markers in patients with NSCLC over time. No changes were observed in markers of satellite cell activation or DNA damage in patients and no group differences were noted with HC. Whole-muscle strength was preserved over time in patients with NSCLC coincident with improved single fibre contractility.
Conclusions: This study is the first to comprehensively examine longitudinal alterations in skeletal muscle fibre size and function in patients with NSCLC and suggests that muscle fibre atrophy occurs during cancer treatment despite weight stability and no changes in conventional clinical measurements of whole body or thigh muscle size over this period.
(© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.)
References: J Clin Endocrinol Metab. 2013 Jun;98(6):2604-12. (PMID: 23589526)
Thorac Cancer. 2021 Jun;12(11):1662-1667. (PMID: 33829665)
Int J Mol Sci. 2022 Dec 06;23(23):. (PMID: 36499737)
Lancet Oncol. 2011 May;12(5):489-95. (PMID: 21296615)
Biochem Biophys Res Commun. 2013 Jun 7;435(3):488-92. (PMID: 23673294)
Cancer Res. 2016 Nov 15;76(22):6631-6642. (PMID: 27680684)
Pancreatology. 2019 Jan;19(1):80-87. (PMID: 30497874)
Nat Rev Clin Oncol. 2018 Apr;15(4):197-198. (PMID: 29405197)
CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946)
J Cachexia Sarcopenia Muscle. 2023 Dec;14(6):2579-2590. (PMID: 37727010)
J Appl Physiol (1985). 2020 Jun 1;128(6):1654-1665. (PMID: 32378975)
J Appl Physiol (1985). 2013 Apr;114(7):858-68. (PMID: 23412895)
Respirology. 2014 Apr;19(3):369-75. (PMID: 24483840)
Am J Clin Nutr. 2013 Sep;98(3):738-48. (PMID: 23902785)
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):926-938. (PMID: 28845591)
Lancet Oncol. 2008 Mar;9(3):269-78. (PMID: 18308252)
Clin Nutr. 2016 Dec;35(6):1359-1365. (PMID: 27010836)
Am J Clin Nutr. 2010 Apr;91(4):1133S-1137S. (PMID: 20164322)
Acta Physiol Scand. 1979 Sep;107(1):39-46. (PMID: 525367)
FASEB J. 2018 Oct;32(10):5495-5505. (PMID: 29750574)
J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):467-82. (PMID: 27239403)
Eur J Appl Physiol. 2014 Jan;114(1):29-39. (PMID: 24122149)
J Natl Cancer Inst. 2009 Jun 16;101(12):860-8. (PMID: 19509357)
Am J Respir Cell Mol Biol. 2020 Feb;62(2):217-230. (PMID: 31461300)
J Physiol. 2014 Oct 15;592(20):4555-73. (PMID: 25038243)
Support Care Cancer. 2019 Jul;27(7):2657-2664. (PMID: 30478673)
Breast Cancer Res Treat. 1999 Oct;57(3):285-90. (PMID: 10617305)
J Clin Invest. 2013 Nov;123(11):4821-35. (PMID: 24084740)
Clin Radiol. 2018 May;73(5):505.e1-505.e8. (PMID: 29317048)
Am J Physiol Cell Physiol. 2018 Nov 1;315(5):C744-C756. (PMID: 30207784)
J Clin Med. 2018 Dec 01;7(12):. (PMID: 30513776)
J Cachexia Sarcopenia Muscle. 2019 Dec;10(6):1183-1194. (PMID: 31436396)
J Appl Physiol (1985). 2014 Jun 15;116(12):1582-92. (PMID: 24790014)
Am J Cardiol. 1997 May 1;79(9):1267-9. (PMID: 9164902)
Int J Cardiol. 2010 Sep 3;143(3):276-82. (PMID: 19327849)
J Pain Symptom Manage. 2012 Jun;43(6):1025-35. (PMID: 22269181)
Acta Oncol. 2016 Sep - Oct;55(9-10):1246-1250. (PMID: 27218150)
J Clin Invest. 1992 May;89(5):1681-4. (PMID: 1569207)
J Cardiopulm Rehabil Prev. 2021 Nov 1;41(6):413-418. (PMID: 33512980)
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):824-838. (PMID: 35080147)
J Appl Physiol (1985). 2019 Dec 1;127(6):1632-1639. (PMID: 31697594)
Obesity (Silver Spring). 2012 Jun;20(6):1313-8. (PMID: 22282048)
معلومات مُعتمدة: R01 AR065826 United States AR NIAMS NIH HHS; R01 HL142081 United States HL NHLBI NIH HHS; T32 HL076122 United States HL NHLBI NIH HHS; U54 GM115516 United States GM NIGMS NIH HHS
فهرسة مساهمة: Keywords: Atrophy; Cachexia; Chemotherapy; Malignancy; Pulmonary disease
تواريخ الأحداث: Date Created: 20230920 Date Completed: 20231228 Latest Revision: 20240523
رمز التحديث: 20240523
مُعرف محوري في PubMed: PMC10751417
DOI: 10.1002/jcsm.13332
PMID: 37727010
قاعدة البيانات: MEDLINE
الوصف
تدمد:2190-6009
DOI:10.1002/jcsm.13332